Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.27
$0.03(2.48%)
At close: 4:00 PM EDT
$1.27
$0.03(2.48%)
Day’s Range― - ―
52-Week Range$0.64 - $1.87
Previous Close$1.19
Volume745.95K
Average Volume (3M)N/A
Market Cap
$132.83M
Enterprise Value$42.95
Total Cash (Recent Filing)$15.04M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding107,121,670
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside214.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$31.08M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Low LeverageMaxCyte reports very high gross margins (historically ~81%–89%) and low leverage (total debt ~$16–18M vs equity ~$168–254M). High product gross margins support scalable profitability as volumes recover, while low debt preserves financial flexibility for multi‑year product and partner investments.
Strong Cash Position With No DebtA cash balance of ~$148M and zero net debt gives the company durable runway to fund commercialization (ExPERT DTX, SeQure), reduce OpEx risk, and withstand milestone timing variability. This liquidity underpins medium‑term execution without immediate financing pressure, supporting strategic flexibility.
Large SPL Partner Pipeline And Milestone UpsideA broad SPL base (29 partners, 30+ programs, multiple clinical programs) creates long‑dated optionality: milestones and royalties can convert program progress into high‑margin, non‑dilutive revenue. This structural licensing model can materially lift recurring economics as partners advance into registrational stages.
Bears Say
Persistent Negative Operating And Free Cash FlowTrailing negative operating and free cash flows (TTM OCF ≈ -$28M, FCF ≈ -$29.5M) indicate ongoing cash burn despite strong gross margins. If core revenue recovery or milestones lag, continued negative FCF will erode reserves and raise financing or dilution risk over the medium term.
Declining Core Revenue TrendCore revenue weakness (25% YoY Q1 decline, multi‑year revenue deterioration) undermines consumables and service growth tied to the installed instrument base. Structural declines reduce operating leverage and make it harder to leverage existing high gross margins into sustained profitability.
Milestone Visibility And Product Commercialization UncertaintyReliance on SPL milestones and nascent product launches creates revenue volatility: management is conservative on additional 2026 milestones and ExPERT DTX/SeQure are early with commercial learning curves. This limits predictability of high‑margin revenue growth in the medium term.
MaxCyte News
MXCT FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was $0.64 and its highest was $1.86 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is $132.83M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.01.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 107,121,670 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (214.96% Upside)
$4.00 (214.96% Upside)
Blogger Sentiment
Neutral
MXCT Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 15.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.43%
Trailing 12-Months
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company that has stabilized near-term revenue, materially reduced operating expenses, and strengthened its strategic positioning through a large enterprise partnership (Genentech), while maintaining a strong balance sheet. These positives were offset by notable year-over-year revenue declines, gross margin pressure due to product mix, and prior partner/program headwinds. Management reiterated guidance and expects a return to growth in H2 2026, with further upside tied to SPL royalties and instrument adoption.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
▲(214.96% Upside)
Ownership Overview
3.01% Insiders
10.47% Mutual Funds
19.37% Other Institutional Investors
63.20% Public Companies and
Individual Investors